Avcu Ferit, Ural A Ugur, Yilmaz M Ilker, Bingol Necati, Nevruz Oral, Caglar Kayser
Departments of Nephrology, Gulhane Military Medical Academy, Bayindir Medical Center, Ankara, Turkey.
Int J Hematol. 2006 Apr;83(3):254-8. doi: 10.1532/IJH97.NA0411.
Adiponectin, an adipocyte-secreted hormone, is an important negative regulator in the immune system and hematopoiesis. In this study, we investigated the association of adiponectin levels with chronic lymphocytic leukemia (CLL) and myeloproliferative diseases (MPDs). We measured adiponectin levels in 19 patients with CLL and 30 patients with MPD (chronic myelogenous leukemia, 15; polycythemia vera, 9; myelofibrosis, 4; essential thrombocythemia, 2). The data were (chronic myelogenous leukemia, 15; polycythemia vera, 9; myelofibrosis, 4; essential thrombocythemia, 2). The data were compared with results from a control group of healthy volunteers who were matched according to age, sex, and body mass index. The adiponectin levels in patients with CLL were lower than in the controls (4.71 +/- 1.33 microg/mL versus 16.61 +/- 3.91 microg/mL; P <.001). They were also significantly lower in patients with MPD than in the controls (8.95 +/- 1.33 microg/mL versus 16.16 +/- 4.77 microg/mL; P <.001). In addition, we compared the adiponectin levels of MPD patients who were treated with interferon (IFN) to the levels of patients who were not treated with IFN. Adipnectin levels were significantly higher in IFN-treated patients (11.03 +/- 1.39 microg/mL versus 6.87 +/- 1.79 microg/mL; P <.001). These results suggest that lymphopoiesis and myelopoiesis negatively influence adiponectin levels. Adiponectin may be related to inflammatory cytokine release. IFN therapy appears to have a positive influence on adiponectin secretion by suppressing inflammatory cytokines. Future studies are needed to prove causality and to provide insight about this hormone's mechanism of action and its potential role regarding the etiology and progression of CLL and MPD.
脂联素是一种由脂肪细胞分泌的激素，是免疫系统和造血过程中的重要负调节因子。在本研究中，我们调查了脂联素水平与慢性淋巴细胞白血病（CLL）和骨髓增殖性疾病（MPD）之间的关联。我们测量了19例CLL患者和30例MPD患者（慢性粒细胞白血病15例；真性红细胞增多症9例；骨髓纤维化4例；原发性血小板增多症2例）的脂联素水平。数据与根据年龄、性别和体重指数匹配的健康志愿者对照组的结果进行了比较。CLL患者的脂联素水平低于对照组（4.71±1.33微克/毫升对16.61±3.91微克/毫升；P<.001）。MPD患者的脂联素水平也显著低于对照组（8.95±1.33微克/毫升对16.16±4.77微克/毫升；P<.001）。此外，我们比较了接受干扰素（IFN）治疗的MPD患者与未接受IFN治疗的患者的脂联素水平。接受IFN治疗的患者脂联素水平显著更高（11.03±1.39微克/毫升对6.87±1.79微克/毫升；P<.001）。这些结果表明淋巴细胞生成和髓细胞生成对脂联素水平有负面影响。脂联素可能与炎症细胞因子释放有关。IFN治疗似乎通过抑制炎症细胞因子对脂联素分泌有积极影响。未来需要进行研究以证明因果关系，并深入了解这种激素的作用机制及其在CLL和MPD的病因和进展方面的潜在作用。
